An Injectable CMCS/γ-PGA/PRP Bioadhesive With Antibacterial, Adhesive, and Regenerative Properties for Infected Wound Healing

Infected traumatic wounds remain a formidable clinical challenge because existing bioadhesives provide only tissue adhesion and lack concurrent antimicrobial and regenerative capabilities. Here, we developed an injectable bioadhesive (CγR) that integrates an “antibacterial–adhesive–regenerative” (AAR) triad by precisely tuning the ratio of carboxymethyl chitosan (CMCS), autologous platelet-rich plasma (PRP), and γ-polyglutamic acid (γ-PGA). CγR exhibits > 99.9% bactericidal efficacy against Escherichia coli and Staphylococcus aureus , delivers instantaneous wet-tissue adhesion (> 3 kPa), and sustains a gradient release of PDGF, TGF-β, and VEGF. In a rat model of infected full-thickness wounds, a single application achieved sterile sealing and complete epithelialization within 6 days, increased collagen deposition by 1.5-fold, and markedly drove macrophage polarization toward the prohealing M2 phenotype. By condensing the conventional “suture–antibiotic–dressing” regimen into a one-step procedure, CγR offers a biosafe and readily scalable platform for managing contaminated complex wounds and holds promise for clinical translation. Graphical The injectable bioadhesive CγR integrates carboxymethyl chitosan (CMCS), platelet-rich plasma (PRP), and γ-polyglutamic acid (γ-PGA) to provide antimicrobial, adhesive, and regenerative effects. CγR bioadhesive exhibits sustained release of growth factors, promotes rapid wound closure, and accelerates tissue regeneration in infected wound models.